このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Creso Pharma マネジメント

マネジメント基準チェック /14

Creso Pharma'sの CEO はWill Layで、 Jan2022年に任命され、の在任期間は 1.08年です。は、会社の株式の0.63%を直接所有しており、その価値はA$ 199.35K 。経営陣と取締役会の平均在任期間はそれぞれ4.1年と1.2年です。

主要情報

Will Lay

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.1yrs
CEOの所有権	0.6%
経営陣の平均在職期間	4.1yrs
取締役会の平均在任期間	1.2yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Will Lay

1.1yrs

在職期間

Mr. William Lay, also known as Will, B.Com (Hons.) serves as Group Chief Executive Officer, Managing Director and Director at Creso Pharma Limited since January 17, 2022 and served as its Executive Vice Pr...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Boaz Wachtel	Co-Founder & Non-Executive Chairman	7.3yrs	AU$167.14k	0.10% A$ 31.9k
Christopher Grundy	Chief Financial Officer	5.3yrs	AU$501.65k	0.047% A$ 15.0k
William Lay	Group CEO	1.1yrs	データなし	0.63% A$ 199.4k
Gian Trepp	Commercial & Marketing Director	4.1yrs	データなし	データなし
Micheline MacKay	MD & Executive Director	1.1yrs	データなし	データなし
Jodi Scott	Executive Director & President of US Operations	less than a year	データなし	10.48% A$ 3.3m
Erlyn Dawson	Joint Company Secretary	4.3yrs	データなし	データなし
Winton Willesee	Joint Company Secretary	4.3yrs	データなし	データなし
Simon H. Buckingham	Consultant	5.7yrs	AU$18.38k	データなし
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	1.3yrs	データなし	データなし

4.1yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: CPHOAの経営陣は経験豊富であると考えられます ( 4.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Boaz Wachtel	Co-Founder & Non-Executive Chairman	7.3yrs	AU$167.14k	0.10% A$ 31.9k
William Lay	Group CEO	1.1yrs	データなし	0.63% A$ 199.4k
Micheline MacKay	MD & Executive Director	1.1yrs	データなし	データなし
Jodi Scott	Executive Director & President of US Operations	less than a year	データなし	10.48% A$ 3.3m
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	1.3yrs	データなし	データなし
Walter Von Wartburg	Member of Scientific Advisory Board	4.1yrs	データなし	データなし
Bruce Linton	Independent Non-Executive Director & Strategic Advisor	2.3yrs	データなし	0.52% A$ 166.1k
Isaac Kobrin	Member of Scientific Advisory Board	no data	データなし	データなし
Felix Gutzwiller	Member of Scientific Advisory Board	5.9yrs	データなし	データなし
Peter Hatfull	Non-Executive Director	less than a year	データなし	データなし
Ben Quirin	Non-Executive Director	less than a year	データなし	データなし

1.2yrs

平均在職期間

71.5yo

平均年齢

経験豊富なボード: CPHOAの取締役会は経験豊富ではない ( 1.2年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Creso Pharma マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Melodiol Global Health Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary

Creso Pharma Limited Announces Board Changes

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Recent updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215 million.

Melodiol Global Health Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.231808 million.

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million.

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 1.010906 million.

Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.

Creso Pharma Limited (ASX:CPH) entered into a binding letter of intent to acquire Abby & Finn, LLC for $2.5 million.

Creso Pharma Limited Announces Board Changes

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

Sierra Sage Secures USD 214,000 Purchase Order from Walmart

Creso Pharma Limited (ASX:CPH) signed a non-binding, non-exclusive heads of agreement to acquire Dr Pickles Pty Ltd.

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Creso Pharma Limited announced that it expects to receive AUD 5 million in funding

Creso Pharma to Develop New Hemp-Based Lozenge Product

Creso Pharma Limited Launches New E-Commerce Channels

Creso Pharma Limited (ASX:CPH) completed the acquisition of Halucenex Life Sciences Inc.

Creso Pharma Limited Launches New Product

Creso Pharma Limited (ASX:CPH) entered into an agreement to acquire Halucenex Life Sciences Inc. CAD 10 million.

Creso Pharma Limited Signs Non-Binding Letter of Intent with ImpACTIVE Holdings Ltd

Creso Pharma Limited Executes A Non-Binding Letter of Intent with Ceres Natural Remedies

Creso Pharma Limited Revises Earnings Guidance for the Fiscal Year 2021

Creso Pharma Limited Announces Distribution Agreement with Route2 Pharm Pvt Ltd

CBD Oil legal in Australia - Creso Pharma Limited to benefit

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14